De Novo Human Cardiac Myocytes for Medical Research: Promises and Challenges

Abstract

The advent of cellular reprogramming technology has revolutionized biomedical research. De novo human cardiac myocytes can now be obtained from direct reprogramming of somatic cells (such as fibroblasts), from induced pluripotent stem cells (iPSCs, which are reprogrammed from somatic cells), and from human embryonic stem cells (hESCs). Such de novo human… (More)
DOI: 10.1155/2017/4528941

2 Figures and Tables

Topics

  • Blog articles referencing this paper

  • Presentations referencing similar topics